Last reviewed · How we verify
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 257 |
| Start date | 2018-08-01 |
| Completion | 2026-08 |
Conditions
- Hodgkin Lymphoma
- Relapsed or Refractory Hodgkin Lymphoma
Interventions
- pembrolizumab
- gemcitabine
- vinorelbine
- liposomal doxorubicin
- Stem cell mobilization and collection
Primary outcomes
- Complete response rate (part 1) — 2 years
Response to pembrolizumab-GVD will be assessed using the RECIL criteria.
Countries
United States